Fatty Liver and Red Wine: Is It Safe to Drink?

Fatty liver disease and red wine is a topic that raises important questions for many people managing their liver health. Whether you have been diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) or alcohol-related liver disease, understanding how red wine and alcohol affect the liver is essential. Despite popular claims about resveratrol offering protective benefits, the evidence tells a more cautious story. This article explains how fatty liver develops, what UK clinical guidance says about alcohol, and which lifestyle changes offer the strongest evidence for improving liver health.

What is fatty liver disease and how does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, and is divided into MASLD (driven by metabolic factors) and ALD (driven by alcohol). Without intervention, both can progress from simple steatosis through to cirrhosis and liver failure.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, impairing the organ's ability to function normally. It is broadly divided into two main types: metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD) and alcohol-related liver disease (ALD). Both share a common endpoint of fat deposition in the liver, but their primary drivers differ.

MASLD develops when the liver processes more fat than it can export or oxidise, typically in the context of obesity, type 2 diabetes, insulin resistance, or high intake of refined carbohydrates and saturated fats. ALD arises directly from the liver's metabolism of ethanol, which generates toxic byproducts including acetaldehyde and reactive oxygen species that damage hepatocytes.^[18][17]

In its early stages, fatty liver is often entirely silent, with no symptoms and liver enzyme levels that may be only mildly elevated or even within the normal range on blood tests. Without intervention, both forms can progress through stages of increasing severity:

• Steatosis (simple fat accumulation)

• Steatohepatitis (fat plus inflammation)

• Fibrosis (scarring of liver tissue)

• Cirrhosis (advanced, irreversible scarring)

• Liver failure or hepatocellular carcinoma in the most severe cases

The risk of progression is most strongly determined by the degree of fibrosis rather than the degree of fat accumulation alone.^[16][3] Fatty liver disease is now one of the most common liver conditions in the UK, affecting an estimated one in three adults to some degree, according to the British Liver Trust.^[9] Early identification and lifestyle modification remain the most effective strategies for halting or reversing progression, particularly in the steatosis and early fibrosis stages.

Is red wine safe to drink if you have a fatty liver?

Red wine is not safe for most people with fatty liver disease, as alcohol burdens an already stressed liver and resveratrol offers no proven clinical benefit in humans. The NHS advises complete abstinence for ALD and advanced fibrosis, and discourages alcohol in MASLD.

For most people with fatty liver disease, the safest approach is to avoid alcohol entirely. The liver is the primary site of alcohol metabolism, and any amount of ethanol places an additional burden on an organ that is already under stress. For people with ALD or with advanced fibrosis or cirrhosis of any cause, complete abstinence is essential and is the advice of both the NHS and the British Liver Trust.

For people with MASLD who do not have advanced fibrosis, UK guidance emphasises avoiding alcohol and, if a person chooses to drink at all, staying strictly within the low-risk limit of no more than 14 units per week spread across several days, with alcohol-free days each week, and never binge drinking.^[2][1] This is a ceiling, not a target, and the safest choice remains not drinking. Anyone with MASLD who is unsure about their alcohol intake should discuss it with their GP rather than relying on general population guidance.

A widely circulated claim suggests that the polyphenol resveratrol, found in red wine, may offer liver-protective benefits. While resveratrol has shown some anti-inflammatory and antioxidant properties in laboratory and animal studies, there is currently no robust clinical evidence in humans demonstrating that drinking red wine protects or improves a fatty liver. The potential harms of the ethanol in wine outweigh any theoretical benefit from resveratrol.

It is also worth noting that red wine contributes to caloric intake. A standard 175 ml glass of red wine contains approximately 160 kilocalories (based on NHS and Drinkaware data), and regular consumption can meaningfully increase total caloric intake, worsening the weight-related drivers of MASLD.^[10]

If you have been diagnosed with fatty liver disease and are unsure about your alcohol intake, speak to your GP, who can arrange liver function tests and provide personalised guidance based on your specific diagnosis and disease stage.

How does alcohol affect the liver even in small amounts?

From the first drink, the liver metabolises ethanol into acetaldehyde, a toxic compound that damages liver cells, promotes fat storage, and triggers inflammation. Even low-level alcohol intake can worsen hepatic steatosis, particularly in those with existing metabolic risk factors.

Alcohol begins to affect the liver from the very first drink, because the liver is responsible for metabolising approximately 90 per cent of all ethanol consumed.^[18][17] When alcohol is broken down by the enzyme alcohol dehydrogenase, it produces acetaldehyde, a highly reactive compound that directly damages liver cells, disrupts mitochondrial function, and triggers an inflammatory response.

Even at low levels of consumption, this metabolic process generates an excess of NADH (a reduced coenzyme), which shifts the liver's biochemistry away from fat oxidation and towards fat synthesis and storage. This is one proposed mechanism by which even modest alcohol intake may promote or worsen hepatic steatosis, particularly in individuals who already have metabolic risk factors, though the clinical significance at very low doses is still an area of active research.

Chronic alcohol use also activates Kupffer cells (the liver's resident immune cells), promoting the release of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-alpha). Sustained inflammation of this kind is associated with fibrosis over time, and this risk is greater with heavier or longer-term drinking.

Key effects of alcohol on the liver include:

• Increased fat synthesis and reduced fat oxidation within hepatocytes

• Direct cellular toxicity from acetaldehyde

• Oxidative stress from reactive oxygen species generated during ethanol metabolism

• Gut microbiome disruption, increasing intestinal permeability and bacterial endotoxin translocation to the liver

• Impaired liver regeneration, reducing the organ's capacity to repair itself

These mechanisms help explain why UK clinical guidance does not support any level of alcohol consumption as safe for people with established liver disease, and why even low-level drinking is discouraged in MASLD. The liver responds to ethanol itself, not to the type of drink it comes from.

What does the NHS recommend about alcohol and liver health?

The NHS recommends no more than 14 units of alcohol per week for the general population, and complete abstinence for anyone with ALD, advanced fibrosis, or cirrhosis. People with MASLD should avoid alcohol and discuss their intake with a GP.

The NHS recommends that adults in the UK drink no more than 14 units of alcohol per week, spread across at least three days, with several alcohol-free days each week. To put this in context, 14 units is roughly equivalent to six pints of average-strength beer or ten small (125 ml) glasses of wine. This guidance applies to the general population and represents a low-risk limit, not a recommended intake.

For people with ALD or with advanced fibrosis or cirrhosis, the NHS and British Liver Trust advise complete abstinence from alcohol. For people with MASLD, guidance emphasises avoiding alcohol; if a person does drink, they should stay within the low-risk limit and discuss their intake with a clinician, as individual circumstances and disease stage matter.

Important safety note for people who drink heavily or regularly: do not stop drinking suddenly without speaking to your GP or a specialist first. Abrupt alcohol cessation in people who are alcohol-dependent can cause serious withdrawal symptoms, including seizures.^[11][12] Your GP can arrange medically supervised withdrawal and refer you to NHS alcohol support services.

NICE guidance (NG49 for MASLD and CG115 for alcohol-use disorders) supports a structured approach to assessment and management.^[3][4] A GP can:

• Arrange liver function blood tests and, where appropriate, calculate a FIB-4 score or arrange a FibroScan or liver ultrasound to assess fibrosis stage

• Refer to a hepatologist or specialist liver service if significant fibrosis or cirrhosis is suspected

• Signpost to alcohol support services, including NHS-funded structured programmes

• Provide brief intervention counselling for hazardous or harmful drinking

Seek urgent medical attention (call 999 or go to A&E) if you or someone else experiences yellowing of the skin or eyes (jaundice), vomiting blood or passing black tarry stools, sudden confusion or difficulty staying awake, severe abdominal swelling with fever, or any rapid deterioration in someone with known liver disease. These may indicate serious complications requiring same-day assessment.

For symptoms such as persistent fatigue, mild abdominal discomfort in the upper right side, or unexplained weight loss, contact your GP promptly. Do not attempt to self-manage suspected liver disease without professional assessment.

Which lifestyle changes can help reverse a fatty liver?

Alcohol avoidance, gradual weight loss of 7 to 10 per cent of body weight, a Mediterranean-style diet, and at least 150 minutes of moderate exercise per week are the most evidence-supported interventions for reversing fatty liver disease.

Fatty liver disease, particularly in its earlier stages, can be significantly improved or even reversed through sustained lifestyle modification, and the evidence base for this is well established. The most impactful changes address the underlying drivers of hepatic fat accumulation: excess caloric intake, physical inactivity, and alcohol consumption.

Alcohol avoidance is strongly recommended for anyone with fatty liver disease. For ALD and for those with advanced fibrosis or cirrhosis, complete abstinence is essential. For MASLD, avoiding alcohol reduces the total metabolic burden on the liver; if a person does drink, they should stay within low-risk limits and seek clinical advice.

Weight loss is the most evidence-supported intervention for MASLD. NICE guidance (NG49) indicates that a sustained reduction of 7 to 10 per cent of body weight is associated with meaningful improvements in liver histology, including reductions in steatosis, inflammation, and fibrosis.^[5][6] Weight loss should be gradual and achieved through a calorie-controlled diet. Very low-calorie diets (typically defined as below 800 kilocalories per day) should only be undertaken under medical supervision, as rapid weight loss can in some circumstances worsen liver inflammation.

Dietary changes that support liver health include:

• Reducing intake of ultra-processed foods, refined sugars, and saturated fats

• Increasing consumption of vegetables, wholegrains, legumes, and oily fish

• Following a Mediterranean-style dietary pattern, which has the strongest evidence base for MASLD^[24][25]

• Limiting fructose-containing drinks, including fruit juices and sugar-sweetened beverages

Regular physical activity independently improves liver fat content, even without significant weight loss. Both aerobic exercise and resistance training have demonstrated benefit. NHS guidelines recommend at least 150 minutes of moderate-intensity activity per week.

Risk stratification and monitoring are an important part of management. NICE NG49 recommends that GPs use the FIB-4 score (calculated from routine blood tests) to assess fibrosis risk and determine whether referral to a specialist liver service is needed.^[3][5] People with a high FIB-4 score or other indicators of significant fibrosis may be referred for further assessment, including transient elastography (FibroScan) or an enhanced liver fibrosis (ELF) test.

For people seeking structured support with weight management, a range of options exists, including NHS Tier 3 weight management services, though access depends on local Integrated Care Board (ICB) pathways and eligibility criteria. Where clinically appropriate following assessment, pharmacological treatment may also be considered. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support; treatment is only recommended where clinically appropriate following assessment.

Regular monitoring by a GP or hepatologist is important to track progress and detect any disease progression early.

Scientific References

1. Alcohol-related liver disease (ARLD).
2. Non-alcoholic fatty liver disease (NAFLD).
3. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
4. NG49 – Short version of draft guideline.
5. NG49 – Full guideline PDF (MASLD: assessment and management).
6. NG49 – Evidence.
7. NG49 – Recommendations for research.
8. Clinical guidelines for alcohol treatment – Introduction (CG115).
9. Liver disease: applying All Our Health.
10. Calories in alcohol.
11. Alcohol-use disorder.
12. Alcohol dependence – Treatment summaries.
13. Physical activity guidelines for adults aged 19 to 64.
14. AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review.
15. Global epidemiological patterns and disease burden of MASLD, MetALD, and ALD.
16. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
17. Alcohol, protein nutrition, and liver injury.
18. Effects of ethanol on hepatic cellular replication and cell cycle progression.
19. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver.
20. Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review).
21. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation.
22. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
23. Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review.
24. Mediterranean Diet and Metabolic Outcomes in NAFLD/MASLD: A Systematic Review and Meta-Analysis.
25. The effectiveness and acceptability of Mediterranean diet and calorie restriction interventions on NAFLD surrogate markers.
26. Structured Exercise Interventions and Hepatic-Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomized Controlled Trials.

Frequently Asked Questions